Welcome to our dedicated page for GLOBALINK INVESTMENT SEC filings (Ticker: GLLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GLOBALINK INVESTMENT's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GLOBALINK INVESTMENT's regulatory disclosures and financial reporting.
Globalink Investment Inc. reported that its stockholders approved a business combination with Alps Life Sciences Inc. and related corporate changes at a special meeting on October 7, 2025. Investors unanimously backed the redomestication merger, under which Globalink will merge into Alps Global Holding Pubco, and the acquisition merger, in which a PubCo subsidiary will merge with Alps so that Alps becomes a wholly owned subsidiary of PubCo.
Stockholders also approved an amendment to Globalink’s charter to remove the requirement that any initial business combination leave the company with at least $5,000,001 of net tangible assets. In connection with the vote, holders of 59,966 public shares chose to redeem their shares for cash, leaving 12,635 public shares outstanding.
Globalink Investment Inc. extended the deadline to complete its initial business combination by one month. On October 4, 2025, the company deposited an Extension Payment of $0.15 per public share, totaling $10,890.15, into its trust account for public stockholders. This payment moves the termination date for completing a merger or similar transaction from October 9, 2025 to November 9, 2025.
This is the company’s twenty-eighth extension since its initial public offering on December 9, 2021, and the fifth of up to six extensions currently permitted under its Amended and Restated Certificate of Incorporation. The company also issued a press release describing the decision, which is filed as an exhibit.
Globalink Investment Inc. entered into a Third Amendment to its merger agreement with Alps Life Sciences Inc. on September 27, 2025. The amendment allows Dr. Tham Seng Kong, in his personal capacity, to contribute all escrow shares from his personal entitlement of merger consideration shares, changing how a portion of his stock-based consideration is held in escrow.
The amendment also extends the deadline for obtaining the written consent of Alps Holdco shareholders, giving more time to secure formal approval for the business combination. The planned transaction will be completed through Alps Global Holding Pubco, which has filed a Form F-4 registration statement that includes a proxy statement/prospectus for Globalink stockholders.
Globalink Investment Inc. proposes a multi-step business combination that will redomesticate Globalink into PubCo and merge Alps Holdco into PubCo as a wholly owned subsidiary, creating a "Combined Company." The proxy/prospectus describes an Exchange Fund to deliver Merger Consideration Shares to Alps Holdco shareholders and states unclaimed Exchange Fund amounts may become property of the Reincorporation Merger Surviving Company if not claimed before escheat.
The filing discloses a proposed amendment to the Globalink charter to remove the net tangible assets minimum of $5,000,001 for consummating an initial business combination, and conditions tying waiver of that Net Tangible Asset Requirement to PubCo satisfying NASDAQ Global Market or NASDAQ Capital Market listing criteria. The record includes support, lock-up and registration rights agreements, a Trust Account waiver by certain subscribers, named Parent and Seller Representatives and signatures dated September 17, 2025.